Lasofoxifen (standaard)

Lasofoxifene (Standard) is the analytical standard of Lasofoxifene. This product is intended for research and analytical applications. Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis[1][2].

180916-16-9

12352100

Estrogen Receptor/ERR; Reference Standards

Others; Vitamin D Related/Nuclear Receptor

Cancer; Inflammation/Immunology

OC1=CC=C2[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CCC2=C1

C28H31NO2

413.55

[1]Lainé M, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12. 23 (1) :54. |[2]Andreano KJ, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther. 2020 Jul. 19 (7) :1395-1405. |[3]Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford) . 2016 Mar;55 (3) :553-63.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-A0037R/

Reference Standards